Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 86

Sort by

Sort Order Select

Journal Articles

Prognostic Significance of Hospitalization Status at Second Cycle of Hypomethylating Agent Induction Therapy in Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Douglas Tremblay, MD, Rafael Madero-Marroquin, MD, Guido Lancman, MD, Alexander Coltoff, MD, Jonathan Feld, MD, Jessica Caro, MD, Nicole Zubizarreta, MPH, Marina Kremyanskaya, Alla Keyzner, MD, Michal Bar-Natan, MD, Shyamala C. Navada, MD, Lewis R. Silverman, Janice L. Gabrilove, MD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 5102.

https://doi.org/10.1182/blood-2019-123288

Published: 2019

Journal Articles

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)

Ahmed Sawas, MD, Hager Elgedawe, George Vlad, PhD, Mikel Lipschitz, M.S., Pei-Hsuan Chen, PhD, Scott J Rodig, MD, Jennifer Kimberly Lue, MD, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Maher Abdul Hay, MD, Karen Khan, BSN, Laine E. Atkins, RN, Aishling M. Rada, RN, Larisa Geskin, MD, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 2908.

https://doi.org/10.1182/blood-2018-99-115269

Published: 2018

Journal Articles

Granulocyte Transfusions for Neutropenic Patients with Perirectal and Perineal Infections

Darwin Roman, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Marina Y. Konopleva, MD PhD, Courtney D. DiNardo, MD MSc, Naval G. Daver, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Steven M. Kornblau, MD, Prithviraj Bose, MD, Michael Andreeff, MD PhD, Emil J. Freireich, MD, Farhad Ravandi, MD, Fleur M. Aung, MD

Blood (2018) 132 (Supplement 1): 2544.

https://doi.org/10.1182/blood-2018-99-117895

Published: 2018

Journal Articles

Procalcitonin As a Potential Biomarker for Differentiating Bacterial Infectious Fevers from Cytokine Release Syndrome

Joseph Maakaron, MD, Sam Penza, MD, Zeinab El Boghdadly, MBBCh, Caron A. Jacobson, MD, Bradley Hunter, MD MPH, Matthew J. Frigault, MD, Jeremy S. Abramson, MD MMSc, Justin Kline, MD, Jonathon B. Cohen, MD MS, Ajay K. Gopal, MD, Utkarsh H. Acharya, DO, Samantha Jaglowski, MD MPH, Philippe Armand, MD PhD

Blood (2018) 132 (Supplement 1): 4216.

https://doi.org/10.1182/blood-2018-99-120065

Published: 2018

Journal Articles

Compared the Effect of Mitroxantrone ( MA) with Idarubicine (IA) for Acute Myeloid Leukemia Induction Therapy

Peilong Lai, Mingyan Wu, Minming Li, Chengxin Deng, Zesheng Lu, Chenwei Luo, Xin Huang, Pengjun Liao, Lisi Huang, Ping Wu, Wang Yulian, Changchun Wan, Wei Ling, Liye Zhong, Suijing Wu, Xin Du, MD PhD, Jianyu Weng, MD

Blood (2018) 132 (Supplement 1): 5229.

https://doi.org/10.1182/blood-2018-99-116234

Published: 2018

Journal Articles

Incidence of Neutropenic Fever at a Safety Net Hospital in Cancer Chemotherapy Patients Receiving Prophylactic Pegfilgrastim Manual Injection Compared to the on-Body Auto-Injector

Atin Jindal, MD, Jan Kover, BPharm, Vanja Raduka, PharmD, R.Ph, Timothy E. O'Brien, MD

Blood (2018) 132 (Supplement 1): 4709.

https://doi.org/10.1182/blood-2018-99-114282

Published: 2018

Journal Articles

Idelalisib for Treatment of Follicular Lymphoma and Chronic Lymphocytic Leukemia in Clinical Trials Versus the Real World: Treatment Duration and Survival Are Associated with Pretreatment Modified Charlson Score

Steven T Bird, PhD PharmD, Natasha Flowers, BA, Fang Tian, PhD MHS, MPH, Donna Przepiorka, MD PhD, Tae Hyun Jung, PhD, Rongrong Wang, MPH, Zebulin Kessler, BS, Corinne Woods, RPh, MPH, Bo Kim, BA, Barry W. Miller, MS, CNP, Michael Wernecke, BA, Stephen McKean, PhD, Clara Kim, PhD, Kate Gelperin, MD MPH, Jeffrey A Kelman, MD MMSc, David J Graham, MD MPH

Blood (2018) 132 (Supplement 1): 2889.

https://doi.org/10.1182/blood-2018-99-116498

Published: 2018

Journal Articles

Predictors for Recurrent 30-Day Unplanned Readmissions in Patients with Hematologic Malignancies

Blood (2017) 130 (Supplement 1): 532.

https://doi.org/10.1182/blood.V130.Suppl_1.532.532

Published: 2017

Journal Articles

Chemosensitive Disease Better Predicts Outcome Than Age Following Autologous Heamatopoietic Stem Cell Transplantation in Elderly Patients with Multiple Myeloma

Christopher Lemieux, MD, Robert Delage, MD, Guy Cantin, MD, Frederic Barabe, MD, Vincent Laroche, MD, Rémy Angers, BSc, Genevieve Gallagher, MD

Blood (2017) 130 (Supplement 1): 5530.

https://doi.org/10.1182/blood.V130.Suppl_1.5530.5530

Published: 2017

Journal Articles

Obinutuzumab (Gazyva) and High-Dose Methylprednisolone (HDMP) Combination for Patients with Chronic Lymphocytic Leukemia (CLL) - a Phase Ib/II Study

Januario E Castro, MD, Carlos I. Amaya-Chanaga, MD, Juliana Velez Lujan, BS,PhD, Michael Choi, MD, Colin McCarthy, BS, Thomas J. Kipps, MD

Blood (2017) 130 (Supplement 1): 1730.

https://doi.org/10.1182/blood.V130.Suppl_1.1730.1730

Published: 2017

Journal Articles

Outpatient Intensive Induction Chemotherapy for Acute Myeloid Leukemia and Advanced Myelodysplastic Syndrome

Frances Linzee Mabrey, MD, Kelda M Gardner, PA-C, Kathleen Shannon Dorcy, RN, PhD, Andrea Perdue, PA-C, Heather Smith, PA-C, Alicyn Marie Davis, ARNP, Cody Hammer, Donelle Rizzuto, RN, Sunny So, RN, Anna Rosen, Kim Quach, Bart L. Scott, MD, Paul C. Hendrie, MD PhD, Mary Beth M. Percival, MD, Roland B. Walter, MD PhD MS, Frederick R. Appelbaum, MD, Elihu H. Estey, MD, Pamela S. Becker, MD PhD

Blood (2017) 130 (Supplement 1): 3851.

https://doi.org/10.1182/blood.V130.Suppl_1.3851.3851

Published: 2017

Journal Articles

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study

Jia Ruan, MD PhD, Peter Martin, FRCPC, MD MS, Paul J Christos, Dr.P.H., M.S., Leandro Cerchietti, MD, Bijal D. Shah, MD, Stephen J. Schuster, MD, Wayne Tam, MD PhD, Amelyn Rodriguez, BSN, RN, OCN, David Hyman, Maria Nieves Calvo Vidal, PhD, Lidia Roman Gonzalez, Sonali M. Smith, MD, Jakub Svoboda, MD, Richard R. Furman, MD, Morton Coleman, MD, John P. Leonard, MD

Blood (2017) 130 (Supplement 1): 154.

https://doi.org/10.1182/blood.V130.Suppl_1.154.154

Published: 2017

Journal Articles

Chimeric Antigen Receptor Induced Cytopenia Differs from Chemotherapy Induced Myelosuppression

Haneen Shalabi, DO, Nirali N Shah, MD, Terry J. Fry, MD, Bonnie Yates, RN, Cynthia Delbrook, RN

Blood (2017) 130 (Supplement 1): 5048.

https://doi.org/10.1182/blood.V130.Suppl_1.5048.5048

Published: 2017

Journal Articles

Addition of Lomustine in the Treatment of Elderly Patients with Acute Myeloblastic Leukemia Improves Survival with Acceptably Increased Infectious Toxicity. a Filo Study

Blood (2017) 130 (Supplement 1): 2587.

https://doi.org/10.1182/blood.V130.Suppl_1.2587.2587

Published: 2017

Journal Articles

Therapeutic Drug Monitoring of Posaconazole in Adult Acute Myeloid Leukemia (Aml) Patients Receiving Posaconazole Prophylaxis during Induction: Experience from a Center with High Invasive Fungal Infection (IFI)Burden

Manju Sengar, Sanyo Dsouza, Raviraj Deshpande, Hasmukh Jain, Murari Gurjar, Sadhana Kannan, Nayana Morajkar, Vikram Gota

Blood (2016) 128 (22): 4005.

https://doi.org/10.1182/blood.V128.22.4005.4005

Published: 2016

Journal Articles

Clinical Impact of Pre-Transplant Microbial Diversity on Transplant Outcomes

Shuhei Kurosawa, Noriko Doki, Masahiro Suyama, Satoshi Sasajima, Aiko Igarashi, Iyo Mimura, Hidetoshi Morita, Yuki Fujioka, MD, Hiroyoshi Nishikawa, MD PhD, Yutaka Shimazu, Wataru Suda, Masahira Hattori, Yuho Najima, Kazuhiko Kakihana, Hisashi Sakamaki, Kenya Honda, Kazuteru Ohashi

Blood (2016) 128 (22): 4577.

https://doi.org/10.1182/blood.V128.22.4577.4577

Published: 2016

Journal Articles

Venous Thromboembolism in Pediatric Cystic Fibrosis

Jessica Knight-Perry, MD, Elinor Towler, BA, Marisa Payan, Brian R. Branchford, MD, Stacey Martiniano, MD, Scott D Sagel, MD, Michael Wang, MD

Blood (2016) 128 (22): 3808.

https://doi.org/10.1182/blood.V128.22.3808.3808

Published: 2016

Journal Articles

Outpatient Stem Cell Mobilization with Intermediate-Dose Cyclophosphamide Is a Safe and Effective Procedure

Alessandra Pompa, MD, Anna Ines Gregorini, MD, Francesca Guidotti, MD, Maria Cecilia Goldaniga, MD, Francesca Gaia Rossi, MD, Riccardo Marcolin, Luca Baldini, MD Prof, Agostino Cortelezzi, MD

Blood (2016) 128 (22): 5734.

https://doi.org/10.1182/blood.V128.22.5734.5734

Published: 2016

Journal Articles

A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with Coexisting Conditions

Carlos I. Amaya-Chanaga, MD, Michael Y. Choi, MD, Natalie Nguyen, B.Sc, Elizabeth DeVore, B.Sc, Colin MacCarthy, B.Sc, Jacqueline Hilger-Rolfe, PhD, M.S., Thomas J. Kipps, MD, PhD, Januario E. Castro, MD

Blood (2016) 128 (22): 2048.

https://doi.org/10.1182/blood.V128.22.2048.2048

Published: 2016

Journal Articles

A Phase Ib/II Study of Combined Obinutuzumab (Gazyva) and High-Dose Methylprednisolone (HDMP) As Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Januario E. Castro, MD, Michael Y. Choi, MD, Carlos I. Amaya-Chanaga, MD, Natalie Nguyen, B.Sc, Colin MacCarthy, B.Sc, Thomas J. Kipps, MD, PhD

Blood (2016) 128 (22): 2051.

https://doi.org/10.1182/blood.V128.22.2051.2051

Published: 2016

NARROW

Prognostic Significance of Hospitalization Status at Second Cycle of Hypomethylating Agent Induction Therapy in Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)

Granulocyte Transfusions for Neutropenic Patients with Perirectal and Perineal Infections

Procalcitonin As a Potential Biomarker for Differentiating Bacterial Infectious Fevers from Cytokine Release Syndrome

Compared the Effect of Mitroxantrone ( MA) with Idarubicine (IA) for Acute Myeloid Leukemia Induction Therapy

Incidence of Neutropenic Fever at a Safety Net Hospital in Cancer Chemotherapy Patients Receiving Prophylactic Pegfilgrastim Manual Injection Compared to the on-Body Auto-Injector

Idelalisib for Treatment of Follicular Lymphoma and Chronic Lymphocytic Leukemia in Clinical Trials Versus the Real World: Treatment Duration and Survival Are Associated with Pretreatment Modified Charlson Score

Predictors for Recurrent 30-Day Unplanned Readmissions in Patients with Hematologic Malignancies

Chemosensitive Disease Better Predicts Outcome Than Age Following Autologous Heamatopoietic Stem Cell Transplantation in Elderly Patients with Multiple Myeloma

Obinutuzumab (Gazyva) and High-Dose Methylprednisolone (HDMP) Combination for Patients with Chronic Lymphocytic Leukemia (CLL) - a Phase Ib/II Study

Outpatient Intensive Induction Chemotherapy for Acute Myeloid Leukemia and Advanced Myelodysplastic Syndrome

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study

Chimeric Antigen Receptor Induced Cytopenia Differs from Chemotherapy Induced Myelosuppression

Addition of Lomustine in the Treatment of Elderly Patients with Acute Myeloblastic Leukemia Improves Survival with Acceptably Increased Infectious Toxicity. a Filo Study

Therapeutic Drug Monitoring of Posaconazole in Adult Acute Myeloid Leukemia (Aml) Patients Receiving Posaconazole Prophylaxis during Induction: Experience from a Center with High Invasive Fungal Infection (IFI)Burden

Clinical Impact of Pre-Transplant Microbial Diversity on Transplant Outcomes

Venous Thromboembolism in Pediatric Cystic Fibrosis

Outpatient Stem Cell Mobilization with Intermediate-Dose Cyclophosphamide Is a Safe and Effective Procedure

A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with Coexisting Conditions

A Phase Ib/II Study of Combined Obinutuzumab (Gazyva) and High-Dose Methylprednisolone (HDMP) As Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only